Extract
Bronchiectasis is a chronic respiratory disease of airway dilatation, where patients typically suffer from respiratory infections, fatigue, sputum, cough, dyspnoea and poor quality of life [1, 2]. This condition has received increased interest over the past years, with important developments in establishing national and international patient registries [3–5], randomised controlled trials of new treatments [6–8] and disease-specific health status questionnaires, such as the Bronchiectasis Health Questionnaire and the Quality of Life Questionnaire – Bronchiectasis [9, 10]. A number of new treatment approaches have been proposed including long term antibiotic therapies and immune modulating drugs [6, 7, 11, 12].
Abstract
A call for action for great awareness and research into airway clearance techniques and pulmonary rehabilitation in bronchiectasis http://bit.ly/2L8F4Va
Footnotes
Conflict of interest: A. Spinou has nothing to disclose.
Conflict of interest: J.D. Chalmers reports grants and personal fees for consultancy, congress travel and/or lectures from GlaxoSmithKline, Grifols, Boehringer Ingelheim and Insmed, grants from AstraZeneca and Bayer Healthcare, personal fees for consultancy, congress travel and/or lectures from Aradigm, Pfizer and Napp, outside the submitted work.
- Received August 13, 2019.
- Accepted August 20, 2019.
- Copyright ©ERS 2019